The procedures convenience, quick results, and minimal downtime are enticing factors that cater to busy lifestyles.
Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
GHK-Cu stimulates the biological signals for collagen synthesis, but those signals still need protein substrate to act on
Treatment of Herpes Simplex Virus Infection
With the right approach, you can continue to live well and actively reduce the impact of DPN on your daily life
The market is inclusive of branded GLP-1 products such as semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity)